Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Idiopathic Pulmonary Fibrosis
Clinical trial register · United States · industry-sponsored

Idiopathic Pulmonary Fibrosis Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9128 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 04 Nov 2026, 03:16 UTC
9128
Studies in scope
industry-sponsored, all four open statuses
4968
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
Florida 13 California 9 Alabama 8 Kansas 7 Colorado 6
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Idiopathic Pulmonary Fibrosis trials in the USA

14 of 9128 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of ORJ-001 for the Treatment of IPF
NCT07869147Idiopathic Pulmonary Fibrosis
Oorja Bio, Inc.
Phase 2
95
Florida, Pennsylvania
2026-10
Recruiting
Trevi Therapeutics
Phase 3
201
Delaware, Florida, North Carolina, Texas
2026-09-30
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
240
Alabama, Florida, Missouri, South Carolina, Tennessee, Texas
2026-07-08
Recruiting
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Louisiana, Missouri, Nevada, New York, North Carolina
2026-06-29
Recruiting
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Active, closed
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Active, closed
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Active, closed
Mediar Therapeutics
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-09-26
Recruiting
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-09-14
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
United Therapeutics
Phase 3
1,850
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2022-09-06
Active, closed
Daewoong Pharmaceutical Co. LTD.
Phase 2
102
Arizona, California, Illinois, Kansas, Massachusetts, Michigan, Missouri, North Carolina
2022-07-29
Active, closed
PureTech
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Indiana, Kansas, North Carolina
2022-07-22
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 4 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/idiopathic-pulmonary-fibrosis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,128 studies in total at the last sync on 04 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Idiopathic Pulmonary Fibrosis.

How many Idiopathic Pulmonary Fibrosis trials are recruiting in the US?

6 of the 14 studies on this page are recruiting new participants as of the 04 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Idiopathic Pulmonary Fibrosis), 14 studies
PhaseStudiesRecruitingShare
Phase 29464.3%
Phase 35235.7%

Most active sponsors

Lead sponsors with the most studies (Idiopathic Pulmonary Fibrosis)
Lead sponsorStudiesRecruiting
Boehringer Ingelheim20
Trevi Therapeutics22
AbbVie11
Bristol-Myers Squibb10
Calluna Pharma AS10
Chiesi Farmaceutici S.p.A.11
Cumberland Pharmaceuticals11
Daewoong Pharmaceutical Co. LTD.10
Mediar Therapeutics10
Oorja Bio, Inc.11

Top states

Top states (Idiopathic Pulmonary Fibrosis), by number of studies with a site there
StateStudies
Florida13
California9
Alabama8
Kansas7
Colorado6
North Carolina6
Arizona5
Illinois5
Missouri5
Connecticut4
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.